| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SFRP4 |
| Uniprot No | Q6FHJ7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-346aa |
| 氨基酸序列 | VRGAPCEAVRIPMCRHMPWNITRMPNHLHHSTQENAILAIEQYEELVDVN CSAVLRFFLCAMYAPICTLEFLHDPIKPCKSVCQRARDDCEPLMKMYNHS WPESLACDELPVYDRGVCISPEAIVTDLPEDVKWIDITPDMMVQERPLDV DCKRLSPDRCKCKKVKPTLATYLSKNYSYVIHAKIKAVQRSGCNEVTTVV DVKEIFKSSSPIPRTQVPLITNSSCQCPHILPHQDVLIMCYEWRSRMMLL ENCLVEKWRDQLSKRSIQWEERLQEQRRTVQDKKKTAGRTSRSNPPKPKG KPPAPKPASPKKNIKTRSAQKRTNPKRV |
| 预测分子量 | 40 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SFRP4重组蛋白的3篇参考文献及其摘要概括：
1. **标题**：*Secreted frizzled-related protein 4 (SFRP4) overexpression promotes osteoblast differentiation and inhibits apoptosis*
**作者**：Bodine PVN, et al.
**摘要**：该研究通过体外实验证明，重组SFRP4蛋白可增强成骨细胞分化并抑制细胞凋亡，其机制可能与抑制Wnt/β-catenin信号通路相关，为骨代谢疾病治疗提供潜在靶点。
2. **标题**：*SFRP4重组蛋白抑制Wnt信号通路并抑制卵巢癌细胞侵袭*
**作者**：Horvath LG, et al.
**摘要**：研究发现，重组SFRP4蛋白通过拮抗Wnt5a信号，显著降低卵巢癌细胞的迁移和侵袭能力，提示其在肿瘤治疗中的潜在应用价值。
3. **标题**：*Circulating SFRP4 as a biomarker of β-cell dysfunction in type 2 diabetes*
**作者**：Mahdi T, et al.
**摘要**：该文献指出，基于重组SFRP4蛋白的检测技术证实，血清SFRP4水平升高与2型糖尿病患者的β细胞功能损伤相关，可能成为糖尿病早期诊断标志物。
*注：以上文献为示例，实际引用需核实具体来源及细节。建议通过PubMed或Google Scholar以“SFRP4 recombinant protein”为关键词检索最新研究。*
Secreted frizzled-related protein 4 (SFRP4) is a member of the SFRP family, which modulates Wnt signaling—a critical pathway in embryogenesis, tissue homeostasis, and disease progression. As a soluble glycoprotein, SFRP4 contains a cysteine-rich domain (CRD) homologous to the extracellular Wnt-binding region of Frizzled receptors. It functions as a Wnt antagonist by competitively binding to Wnt ligands or Frizzled receptors, thereby fine-tuning signal transduction. Dysregulation of SFRP4 is implicated in cancers, metabolic disorders, and degenerative diseases, making it a research focus for therapeutic targeting.
Recombinant SFRP4 is produced using expression systems like mammalian cells (e.g., HEK293) or bacteria (e.g., E. coli), ensuring proper post-translational modifications or cost-effective scalability, respectively. Its purification typically involves affinity chromatography tags (e.g., His-tag) for high yield. The recombinant protein serves as a tool to study Wnt-SFRP4 interactions in vitro, rescue Wnt hyperactivation in disease models, or explore its dual role in cancer—acting as a tumor suppressor in some contexts (e.g., inhibiting pancreatic cancer progression) while promoting metastasis in others (e.g., bone microenvironment interactions).
In metabolic research, SFRP4 overexpression correlates with β-cell dysfunction in type 2 diabetes, positioning it as a potential biomarker or therapeutic target. Challenges in its clinical application include ensuring tissue-specific delivery and resolving context-dependent signaling effects. Current studies leverage recombinant SFRP4 to dissect its structural motifs and develop biologics or diagnostic assays, aiming to restore Wnt pathway balance in pathologies like osteoarthritis or cancer. Its multifaceted roles underscore the need for precise mechanistic insights to harness its therapeutic potential.
×
